transitioning from semaglutide to tirzepatide dosing Switch Wegovy Mounjaro: Complete Patient Guide Switching between weight-loss medications -

Researchers have shown improvements in healthspan-related measures in mice, but no study has demonstrated lifespan extension in humans, and the evidence remains preliminary even in animal models

Clinical Evidence: GI Interactions SURMOUNT-1 showed 31% nausea rates with tirzepatide, peaking during dose escalations when gastric sensitivity is highest

Long-term users often report better energy than before treatment due to benefits of weight loss including improved sleep, reduced joint pain, better fitness, and improved metabolic health

Tirzepatide works by reducing your appetite and slowing down the movement of food from the stomach to the small intestine